Levetiracetam-Induced Systemic Lupus Erythematosus
| Autor: | Teja Kulkarni, Saourabh Rajesh Desai, Rahul Baviskar, Janhavee Praveen Jadhav, Praveen Pratap Jadhav |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
medicine.medical_specialty
Systemic lupus erythematosus Anti-nuclear antibody business.industry General Medicine medicine.disease Dermatology Rash Education Discontinuation Epilepsy immune system diseases medicine Levetiracetam medicine.symptom skin and connective tissue diseases business Adverse effect Adverse drug reaction medicine.drug |
| Zdroj: | Journal of the Royal College of Physicians of Edinburgh. 51:58-60 |
| ISSN: | 2042-8189 1478-2715 |
| Popis: | Systemic lupus erythematosus (SLE) is a rare autoimmune disorder in a physician's practice, commonly presenting in young females. It is rare for SLE to present at a late age. Though SLE is idiopathic, sometimes it can present as an adverse reaction to drugs. Quite a few drugs are implicated in this process. However, there are no reports of levetiracetam causing SLE. Here, we present a case of 62-year-old female presenting with SLE after consumption of levetiracetam for 1 year for her epilepsy. Erythematosus rash was her main symptom. This was associated with a strong positivity of antinuclear antibody. The symptoms remitted completely after the discontinuation of levetiracetam, suggesting them to be because of drug-induced lupus (DIL). DIL differs from SLE in being mild, affecting atypical age groups and resolving completely on withdrawal of the drug. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|